OrphoMed is a clinical-stage pharmaceutical company focused on the development of novel first-in-class dimer conjugates with superior therapeutic profiles. The Company is leveraging its DIMERx™ technology to address the problem of visceral hypersensitivity and pancreatitis in the treatment of gastrointestinal disorders and the unmet medical needs in the treatment of both peripheral neuropathic and systemic nociceptive pain. OrphoMed is also developing potent non-opioid and opioid conjugates to treat acute and chronic nociceptive pain.